It all started in 1356 when a young man called Philip saved his father. As the fourth son of the French king, Philip had little hope to ever do something significant. However, at the battle of ...

Charles River Laboratories International, Inc. (CRL)'s share was trading at $136.25 as of 28 th May. CRL’s trailing and forward P/E were 25.07 and 14.41 respectively according to Yahoo Finance.

Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation ...

City dwellers can now safely paddle and even swim in their urban river. Meanwhile, here in Massachusetts, the Charles River suffers sewage discharges with every large rainstorm, spreading bacteria ...

The FDA's new policy to phase out animal testing caused a significant 28% drop in Charles River Labs' stock. Click to read more on why I rate CRL a Sell.

The bustling streets, rolling green hills and verdant river valleys of Worcestershire are blessed with some of the most beautiful pubs in all England, each a rare jewel in the county's crown.

Charles River (CRL) also projected its 2025 operating margin to drop slightly below the estimated level for 2024 on an adjusted basis. The company expects to issue its full 2025 outlook with its ...

Charles River isn’t the only CRO to have struggled in the third quarter. Irish firm Icon reported third-quarter revenue of $2.03 billion, underperforming analyst expectations of $2.14 billion ...

Charles River now expects 2024 adjusted profit between $10.10 and $10.30 per share, compared with its prior forecast range of $9.90 to $10.20 per share.

Charles River’s global team of nearly 200 neuroscientists work across drug discovery and development, from basic research to regulatory approval, providing the translational science, range of ...

WATERTOWN – It's no secret that Boston traffic is a major issue. Two men want to change that by launching a ferry on the Charles River from Watertown to Boston. They're calling it the Wada ...

Contract drug developer Charles River Laboratories cut its annual forecasts on Thursday as it warned of worsening demand from drugmakers and a persistently low appetite for clinical trials from ...